Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK159802 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving treatment sequence 1 : Cohort 1 | EXPERIMENTAL | Eligible subjects will receive placebo, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms. |
| Subjects receiving treatment sequence 2 : Cohort 1 | EXPERIMENTAL | Eligible subjects will receive GSK159802 150 micrograms, placebo, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms. |
| Subjects receiving treatment sequence 3 : Cohort 1 | EXPERIMENTAL | Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, placebo, GSK159802 900 micrograms and GSK159802 1200 micrograms. |
| Subjects receiving treatment sequence 4 : Cohort 1 | EXPERIMENTAL | Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, placebo and GSK159802 1200 micrograms. |
| Subjects receiving treatment sequence 5 : Cohort 1 | EXPERIMENTAL | Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and placebo. |
| Subjects receiving treatment sequence 1 : Cohort 2 | EXPERIMENTAL | Eligible subjects will receive placebo, salmeterol, GSK159802 low dose (LD) and GSK159802 maximum tolerated dose (MTD). |
| Subjects receiving treatment sequence 2 : Cohort 2 | EXPERIMENTAL | Eligible subjects will receive salmeterol, GSK159802 MTD, placebo and GSK159802 LD. |
| Subjects receiving treatment sequence 3 : Cohort 2 | EXPERIMENTAL | Eligible subjects will receive GSK159802 LD, placebo, GSK159802 MTD and salmeterol. |
| Subjects receiving treatment sequence 4 : Cohort 2 | EXPERIMENTAL | Eligible subjects will receive GSK159802 MTD, GSK159802 LD, salmeterol and placebo. |
| Subjects receiving treatment sequence 1 : Cohort 3 | EXPERIMENTAL | Eligible subjects will receive placebo, salmeterol, GSK159802 300 micrograms and GSK159802 1200 micrograms. |
| Subjects receiving treatment sequence 2 : Cohort 3 | EXPERIMENTAL | Eligible subjects will receive salmeterol, GSK159802 1200 micrograms, placebo and GSK159802 300 micrograms. |
| Subjects receiving treatment sequence 3 : Cohort 3 | EXPERIMENTAL | Eligible subjects will receive GSK159802 300 micrograms, placebo, GSK159802 1200 micrograms and salmeterol. |
| Subjects receiving treatment sequence 4 : Cohort 3 | EXPERIMENTAL | Eligible subjects will receive GSK159802 1200 micrograms, GSK159802 300 micrograms, salmeterol and placebo. |
| Subjects receiving treatment sequence 5 : Cohort 3 | EXPERIMENTAL | Eligible subjects will receive GSK159802 1200 micrograms, salmeterol, GSK159802 300 micrograms and placebo. |
| Name | Type | Description |
|---|---|---|
| GSK159802 | DRUG | GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler. |
| Placebo | DRUG | Subjects will receive placebo administered using DISKUS inhaler. |
| Salmeterol | DRUG | Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler. |
Inclusion criteria: * Body mass index within the range 18.5-29.9 (kg/m2) * Current non-smokers who have not used any tobacco products in the 6-month period preceding the screening visit and have a pack history of \< 10 pack years. Additional criteria for Cohorts 2 and 3 only (Asthmatic Patients): ...
GSK159802 is an investigational small molecule developed by GSK plc for chronic obstructive pulmonary disease, a respiratory condition. It is a Phase 1 clinical candidate and has not been approved for any use. It was studied in a completed early-stage trial in healthy male volunteers and asthmatics.
GSK159802 is being developed for pulmonary disease, chronic obstructive pulmonary disease (COPD). It remains investigational and is not an approved COPD therapy. Its only recorded clinical study enrolled 43 participants and has completed, so no confirmed therapeutic use in COPD has been established.
GSK159802 targets ADRB2, the beta-2 adrenergic receptor, and acts as an agonist at that receptor. ADRB2 agonism is the mechanism of bronchodilator drugs used in respiratory disease. GSK159802 is a small molecule agonist developed by GSK plc for chronic obstructive pulmonary disease.
GSK159802 is made and developed by GSK plc, which trades under the ticker GSK. The compound is an investigational small molecule in the company's respiratory pipeline, being studied for chronic obstructive pulmonary disease. GSK plc is the sole developer identified for this asset.
GSK159802 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any regulator. One Phase 1 trial has been completed, with no active trials currently recorded for the program.
GSK159802 has been studied in one completed Phase 1 trial, NCT00364273, titled GSK159802 In Healthy Male Subjects And Asthmatics. It enrolled 43 male participants aged 18 years and older in the United Kingdom, was randomized and controlled, and included healthy volunteers.